Literature DB >> 22476346

Expedient chemical synthesis of 75mer DNA binding domain of MafA: an insight on its binding to insulin enhancer.

Sara Pellegrino1, Chiara Annoni, Alessandro Contini, Francesca Clerici, Maria Luisa Gelmi.   

Abstract

An expedient chemical synthesis of a 75mer peptide corresponding to the DNA binding domain (DBD, 227-301) of the human MafA leucine zipper transcription factor is reported. The application of microwave-assisted solid phase peptide synthesis (MW-SPPS) with a protocol modified respect to the standard one allowed obtaining the desired 75mer peptide in a short time with high quantity and optimal purity. MW-SPPS methodology was thus demonstrated as a valuable alternative to recombinant methods to obtain protein domains. Considering that recent findings suggest an involvement of MafA in the pathogenesis of diabetes mellitus, we also performed circular dichroism studies both on DBD folding and its interaction with MafA recognition element (MARE) on insulin enhancer. From our results, it was evicted that a disorder to order transition occurs after DBD interaction with insulin MARE which is mediated by specific structural elements on the N-terminus of the DBD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476346     DOI: 10.1007/s00726-012-1274-2

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  7 in total

1.  Class I major histocompatibility complex, the trojan horse for secretion of amyloidogenic β2-microglobulin.

Authors:  Levon Halabelian; Stefano Ricagno; Sofia Giorgetti; Carlo Santambrogio; Alberto Barbiroli; Sara Pellegrino; Adnane Achour; Rita Grandori; Loredana Marchese; Sara Raimondi; P Patrizia Mangione; Gennaro Esposito; Raya Al-Shawi; J Paul Simons; Ivana Speck; Monica Stoppini; Martino Bolognesi; Vittorio Bellotti
Journal:  J Biol Chem       Date:  2013-12-13       Impact factor: 5.157

2.  Crystal structures of H-2Db in complex with the LCMV-derived peptides GP92 and GP392 explain pleiotropic effects of glycosylation on antigen presentation and immunogenicity.

Authors:  Ida Hafstrand; Daniel Badia-Martinez; Benjamin John Josey; Melissa Norström; Jérémie Buratto; Sara Pellegrino; Adil Doganay Duru; Tatyana Sandalova; Adnane Achour
Journal:  PLoS One       Date:  2017-12-18       Impact factor: 3.240

3.  A Comprehensive Survey of the Roles of Highly Disordered Proteins in Type 2 Diabetes.

Authors:  Zhihua Du; Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2017-09-21       Impact factor: 5.923

4.  β-Hairpin mimics containing a piperidine-pyrrolidine scaffold modulate the β-amyloid aggregation process preserving the monomer species.

Authors:  S Pellegrino; N Tonali; E Erba; J Kaffy; M Taverna; A Contini; M Taylor; D Allsop; M L Gelmi; S Ongeri
Journal:  Chem Sci       Date:  2016-10-07       Impact factor: 9.825

5.  Rational Design of a User-Friendly Aptamer/Peptide-Based Device for the Detection of Staphylococcus aureus.

Authors:  Luca Ronda; Alessandro Tonelli; Elisa Sogne; Ida Autiero; Francesca Spyrakis; Sara Pellegrino; Giorgio Abbiati; Elisa Maffioli; Carsten Schulte; Riccardo Piano; Pietro Cozzini; Andrea Mozzarelli; Stefano Bettati; Francesca Clerici; Paolo Milani; Cristina Lenardi; Gabriella Tedeschi; Maria Luisa Gelmi
Journal:  Sensors (Basel)       Date:  2020-09-02       Impact factor: 3.576

6.  NoPv1: a synthetic antimicrobial peptide aptamer targeting the causal agents of grapevine downy mildew and potato late blight.

Authors:  Monica Colombo; Simona Masiero; Stefano Rosa; Elisabetta Caporali; Silvia Laura Toffolatti; Chiara Mizzotti; Luca Tadini; Fabio Rossi; Sara Pellegrino; Rita Musetti; Riccardo Velasco; Michele Perazzolli; Silvia Vezzulli; Paolo Pesaresi
Journal:  Sci Rep       Date:  2020-10-16       Impact factor: 4.379

7.  Tuning PFKFB3 Bisphosphatase Activity Through Allosteric Interference.

Authors:  Helena Macut; Xiao Hu; Delia Tarantino; Ettore Gilardoni; Francesca Clerici; Luca Regazzoni; Alessandro Contini; Sara Pellegrino; Maria Luisa Gelmi
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.